Abiraterone Therapy for Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 321
Special Issue Editors
Interests: prostate cancer; renal cell carcinoma; urothelial carcinoma; robotic surgery; laparoscopy
Interests: prostate cancer; drug resistance; renal cell carcinoma; bladder cancer; trans-differenciation
Special Issue Information
Dear Colleagues,
Abiraterone is a second-generation AR antagonist. It was first approved for high-risk mCRPC patients and was shown to prolong OS. Subsequently, it was also approved for high-risk mHSPC patients. Its therapeutic effect is mediated by CYP17 inhibition, which suppresses testosterone and dihydrotestosterone production. Although real-world evidence has accumulated over time since its approval, issues remain regarding adverse events, drug resistance, and patient-specific treatment sequencing. Several underlying mechanisms of Abiraterone resistance, such as intracellular self-production of androgens, AR mutation, amplification, AR splice variants, abnormal expression of AR co-activators, or co-repressors, glucocorticoid receptor upregulation have been proposed. This Special Issue calls for basic, clinical studies and reviews of “Abiraterone Therapy for Prostate Cancer”. The publication of this Special Issue is expected to improve our understanding of drug therapy for metastatic prostate cancer and prolong patient outcomes. We look forward to receiving your contributions.
Prof. Dr. Yen-Chuan Aaron Ou
Dr. Yasutaka Yamada
Dr. Junryo Rii
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- castration-resistant prostate cancer
- androgen deprivation therapy
- treatment sequencing
- AR splice variants
- quality of life
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
